Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.
Patients with localized muscle-invasive bladder cancer who received radiation plus the immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical study published in Clinical Cancer Research, a journal of the AACR.
